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Lymphadenectomy performed in patients with melanoma 
immediately after the detection of metastasis in the sentinel 
node has a real impact on the fate of only a few patients. 
Instead, it is a procedure that causes very severe adverse con-
sequences. The question we have to ask ourselves is: In what 
number of patients do we cause complications by performing 
unnecessary procedures in order to save the few who need it?
In postoperative specimens after lymphadenectomy due to 
metastases in the sentinel node, metastases in non-sentinel lymph 
nodes are detected only in 18–30% of cases [1–4]. It means that 
in 70–82% patients all melanoma lesions were removed during a 
previous biopsy of the sentinel node within the entire lymphatic 
flow. So it had been not only a diagnostic procedure, but also 
a therapeutic one. It means that in the vast majority of patients 
(even 80%) lymphadenectomy was unnecessary from therapeutic 
point of view. Instead, it was burdened with a very high percen-
tage of adverse consequences and complications. In the case of 
axillary lymphadenectomy, complications affect 50% procedures, 
and in the case of inguinal lymphadenectomy – as much as 90% 
[5–7]. These complications and adverse consequences are mainly: 
lymphorrhea, wound infections, sensory disturbances and lym-
phoedema. Especially lymphoedema is extremely troublesome 
and actually does not respond to treatment. 
In about 80% patients with metastases to the sentinel node 
there is no need to remove lymph nodes. There is no doubt 
about that. This procedure is being performed because it is not 
yet clear which patients belong to these 80% and which do not. 
This situation is not new in skin melanoma surgery. It has 
been discussed for decades whether regional lymph nodes 
should be excised immediately after the excision of the pri-
mary lesion in patients with skin melanoma of intermediate 
thickness or whether the excision should be delayed till clini-
cally detectable metastases occur and only then should they 
be removed. The delay of lymphadenectomy was supported 
by the fact that lymph node metastases occurred only in 
a minority of patients and performing this procedure in all 
melanoma patients exposed most of them to unnecessary, 
but very burdensome, complications. On the other hand, lym-
phadenectomy was immediately supported by the conviction 
that if the procedure was performed quickly, the metastases 
from lymph nodes would be removed before they become 
a source of distant metastases. However, there was no me-
thod to indicate which patients had already developed lymph 
node metastases. Therefore, all patients were considered for 
lymphadenectomy. The solution to the problem was a sentinel 
node biopsy, a method that allowed for detecting clinically 
detectable metastases in lymph nodes. This made it possi-
ble to select those patients in whom lymphadenectomy was 
unjustified. However, in patients with identified metastases to 
the sentinel node, it was known that the process of lymphatic 
metastases had already begun and that lymphadenectomy 
was justifiable [8, 9]. 
As time went by and new clinical data were collected, 
it turned out that in most patients lymph node metastases 
occur only in the sentinel node. The excision of the sentinel 
node removes the whole cancer from the regional lymph 
nodes. Therefore, there is no point in removing the remaining 
lymph nodes.
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The problem, again decades later, is that the same thing 
boils down to questions: How to identify patients with me-
tastases to non-sentinel nodes? Should lymphadenectomy 
be performed in all patients with metastases to the sentinel 
node or should we wait and perform lymphadenectomy only 
in those patients whose metastases in other lymph nodes are 
clinically manifested? If so, won’t we make the prognosis worse 
for the patients? Clearly, we are waiting for a method that will 
allow us to identify those people who suffer from metastases 
to non-sentinel nodes. Such a method would save the majority 
of patients with metastasis to the sentinel node, unnecessary 
consequences and complications after the surgery. 
However, another equally important question arises: Is it 
necessary to perform lymphadenectomy as soon as possible 
in those 20% patients with metastases in non-sentinel nodes? 
There are two theories on solid cancer spreading. The first 
one, the “incubator” theory, is attributed to William Halsted. It 
dates back to the turn of the 19th and 20th centuries. According 
to it, the metastases from the primary lesion first get to the re-
gional lymph nodes only through the lymphatic route. Cancer 
cells multiply within these lymph nodes but do not penetrate 
further. This happens only when the number of cancer cells 
reaches critical mass. This is when the hematogenous routes 
of metastatic spread to distant organs begins. According to 
this theory, if lymph nodes filled with metastases could be 
removed at the right time before the distant metastases be-
gan to develop, the further progress of the disease would be 
stopped and cured [10]. 
This theory was the reason why in the first half of the 
twentieth century the extent of surgical procedures escalated, 
believing that the more extensive the operation would be, the 
greater the chance that the cancer would be excised in its 
entirety and prevent the development of distant metastases. 
The best example were the procedures performed in patients 
with breast cancer. Although the extent of resection was even 
monstrous, this practice was effective only in some patients. 
In most cases, escalation of the resection extent proved to be 
ineffective. Patients were still dying from distant metastases 
and the degree of mutilation by surgery was unacceptable. 
The second theory of the cancer spread is the so-called 
“marker” theory. According to it, metastases develop in parallel 
by hematogenous and lymphatic routes. The discovery of 
lymph node metastases only proves that cancer cells have 
a phenotype capable of metastasis and that the process has 
already begun [10]. 
There are many indications that in melanoma patients both 
scenarios are likely, but they occur in different proportions. 
Among melanoma patients, there are 5 basic groups [11]. The 
first two groups are patients with no metastases in regional 
lymph nodes. The larger of these two groups are those patients 
where cancer did not spread to lymph nodes or distant organs. 
In these patients, the biopsy of the sentinel lymph node brings 
true prognostic information, but the lymphadenectomy after 
the biopsy does not bring any benefits. The second group con-
sists of patients with no metastases in regional lymph nodes, 
however, there were metastases to the distant organs through 
hematogenous route. In these patients, a negative biopsy of the 
sentinel node results in false negative prognostic information. 
Lymphadenectomy is not justified and does not change the 
fate of patients in whom distant metastases develop anyway. 
In the other three groups there are people where metasta-
ses to regional lymph nodes occurred. The largest group are 
patients in whom both lymph node and distant metastases 
were formed very early, before the primary lesion resection. 
In these patients the biopsy of the sentinel node brings true 
prognostic information, but early lymphadenectomy – as soon 
as it is known that the sentinel node contains a metastasis – 
does not change their fate, because they already have distant 
metastases, which determine their survival time. 
The last two groups are people who, according to Halsted’s 
theory, first develop lymph node metastases and only then 
develop distant ones. One group includes those in whom 
clinically undetectable lymph node metastases start to func-
tion as a source of distant metastases after reaching the size 
of clinically detectable metastases. In such cases, the biopsy 
of the sentinel node brings true prognostic information. Early 
lymphadenectomy immediately after confirmation of me-
tastasis in the sentinel node is not justified, as delaying it till 
detectable metastases manifest is safe. However, late lympha-
denectomy and removal of cancer from the regional lymphatic 
flow prevent the development of distant metastases and end 
the course of the disease. 
The last group and the only one in which early lympha-
denectomy is justified are patients with regional lymph node 
metastases, which may be a source of distant metastases alre-
ady at the stage of clinically detectable metastases (detected 
only by biopsy of a sentinel node). In such patients, a sentinel 
node biopsy provides true prognostic information and early 
lymphadenectomy may be crucial for survival. However, this 
is a very small group of patients with melanoma [11]. If we 
add to this the fact that most of these people have metasta-
ses in sentinel nodes and all melanoma lesions are removed 
during a sentinel node biopsy, then the group in which early 
supplemental lymphadenectomy is justified turns out to be 
even smaller. 
The reasoning presented above turns out to be confirmed 
by the research carried out so far. Early lymphadenectomy did 
not affect overall survival in any of the randomized trials perfor-
med in patients with melanoma with no clinically detectable 
lymph node metastases. This applies both before and after the 
introduction of a sentinel node biopsy [11]. These observations 
were the reason for two randomized clinical trials aimed at as-
sessing the impact of early lymphadenectomy on the survival 
of patients with metastases to sentinel nodes. 
The first one, the DeCOG-SLT study, was a multi-center, 
randomized, third phase study in which patients with torso 
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and limb melanoma were included and treated in 41 centers 
in Germany [12]. Patients with metastases in sentinel nodes 
were randomly assigned 1:1 to 2 arms of the study. Lym-
phadenectomy was performed on one arm in the case of 
the second arm the patients were carefully monitored with 
a regional lymph node ultrasound every 3 months. In this arm 
lymphadenectomy was performed only in patients in whom 
regional lymph node metastases were clinically manifested. 
The first priority end point of the trial was the time of survival 
without distant metastases. Ultimately, 483 patients agreed to 
participate in the study. After three years of follow-up, 74.9% of 
patients undergoing lymphadenectomy and 77.0% of patients 
undergoing observation had survived without distant metasta-
ses. The difference was statistically insignificant (p = 0.87). The 
results of the total survival analysis were similar. In the group 
of patients undergoing lymphadenectomy, 81.2% of patients 
were still alive after 3 years, which referred to 81.7% of patients 
in the group of patients under observation. The difference was 
also not statistically significant. 
The second study, MSLT-II, was a multi-center, international 
study of the third phase, in which 63 centers were involved 
[13]. In total, 1934 patients were analyzed for survival time till 
death due to melanoma. As in the previous study, patients 
with sentinel node metastases were randomly assigned to 
a group where an immediate completion lymphadenectomy 
was performed or to a group where they were observed, 
and lymphadenectomy was performed only when the re-
gional lymph node metastases were clinically manifested. 
The ultrasound examination of regional lymphatic flow was 
performed every 4–6 months. The percentage of alive patients 
(melanoma-specific survival) after 3 years in both groups was 
the same and amounted to 86.1%. The researchers found 
that the percentage of relapse-free survival was higher in the 
group undergoing immediate lymphadenectomy than in the 
group under observation, but it was caused by relapses within 
the unremoved regional lymph nodes and not by distant 
metastases. The difference in relapse-free survival was at the 
statistical significance limit (p = 0.05) and did not translate 
into the percentage of melanoma-specific survival. The rese-
archers concluded that immediate lymphadenectomy after 
the diagnosis of metastasis in the sentinel node improved the 
indicators of regional disease control and provided prognosis 
information, but did not improve melanoma-specific survival. 
The results of both randomized studies cited above aro-
used great controversy. Opponents point to numerous limi-
tations in the usefulness of their results, which are mainly due 
to the fact that the time taken to evaluate survival is too short. 
Therefore, at the end it is worth to quote the results of the 
latest meta-analysis published in April 2019 in the Journal of 
Surgical Research [4]. The researchers analyzed the fate of 7966 
patients who participated in 12 studies. Calculations showed 
that immediate regional lymphadenectomy performed after 
detecting metastasis in the sentinel node significantly impro-
ved the percentage of progression-free survival after 3 years 
(71.0% compared to 66.2% in the observation group; p = 0.02) 
and after 5 years (48.3% compared to 47.8%; p = 0.02). However, 
there was no difference in melanoma-specific survival after 
both 3 and 5 years (5-year survival: 68.4% compared to 69.8% 
in the observation group; p = 0.78), as well as no difference 
in total survival after 5 years (68.2% compared to 78.9% in the 
observation group; p = 0.78). The authors concluded that im-
mediate regional lymphadenectomy in patients with sentinel 
node metastasis significantly improved the percentage of 
disease-free survival after 3 and 5 years, but it did not translate 
into improved melanoma-specific or total survival [4]. 
Summarizing the presented trial results, it seems that the 
answer to the question: “Is it justified to perform lymphadenecto-
my in patients with metastases in the sentinel node?” is: No. Ho-
wever, this answer must be subject to at least two reservations. 
First, the results were obtained under specific conditions 
created by the clinical trials. Reproducing these conditions in 
reality is not always possible. In clinical trials, patients under 
observation were regularly subject to ultrasound examinations 
in order to detect a clinically detectable disease as early as 
possible. If performing a regular ultrasound surveillance is not 
possible, it may not be safe to give up lymphadenectomy in 
favor of observation. The patient should then be qualified for 
lymphadenectomy. 
Secondly, lymphadenectomy should be performed when 
there are other factors that may cause lymphadenopathy in 
patients. Especially that it can effectively mask the relapse of 
the disease despite careful ultrasound surveillance. 
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